Therapy News and Research

RSS

Empire implements AGA, ACG guidelines for evaluation and management of dyspepsia and PUD

Empire BlueCross BlueShield today announced an initiative to inform and educate physicians and consumers about important findings from the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) related to a little known but common infection that is a precursor to serious stomach ailments.

7 Apr 2011

Mandometer method to treat eating disorders receives FDA clearance

The U.S. Food and Drug Administration announced on March 31 that it had cleared Mandometer® for the treatment of patients with eating disorders.

7 Apr 2011

Fish oil can serve as beneficial booster for tamoxifen breast cancer therapy

Breast cancer is the second most common cancer among women, with more than 200,000 women diagnosed each year. Being exposed to estrogen over a long period of time is one factor that can increase a woman's risk of developing the disease.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

Roundup: Minn. insurers to return profits above 1% from state plans; Fla. Medicaid managed care costs questioned

In part of the continuing change to Minnesota's business with health insurance plans, the state announced Tuesday that four major health plans agreed to a 1 percent cap on their profits on state business. The one-cap means that the plans -- BlueCross BlueShield, HealthPartners, Medica, and UCare -- will return any profit above 1 percent to the state next April.

7 Apr 2011

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced the publication of Phase III PROCHIEVE® (progesterone gel) data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-reviewed journal of the International Society of Ultrasound in Obstetrics & Gynecology.

7 Apr 2011

New Pipeline Embolization Device receives FDA approval for treatment of brain aneurysms

The U.S. Food and Drug Administration today approved a new device that provides neurointerventional surgeons with another tool to treat brain aneurysms without performing open surgery.

7 Apr 2011

USPTO issues notice of allowance to Mirna's mir34a patent application

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed patent claims related to the therapeutic application of the potent tumor suppressor microRNA, mir34a.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

Progesterone gel can reduce preterm birth in women with short cervix

A groundbreaking clinical study of a new method for preventing premature birth in millions of women each year, published in the medical journal Ultrasound in Obstetrics & Gynecology, shows that the rate of early preterm delivery in women can be reduced by 45 percent - simply by treating pregnant women at risk with a low-cost gel of natural progesterone during the midtrimester of pregnancy until term.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Estrogen therapy for menopause, study looks at risks-benefits

...

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011.

6 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

ICD therapy can improve ischemic cardiomyopathy survival rates

Most patients with ischemic cardiomyopathy and dilated cardiomyopathy who have an implantable cardioverter-defibrillator now live more than seven years and those ICD patients with hereditary heart disease can live for decades, based on a scientific paper that will be presented at the American College of Cardiology Scientific Sessions in New Orleans, April 1-3.

6 Apr 2011

Early Intensive Behavioural Intervention in autism continues to be questioned in Quebec

Early Intensive Behavioural Intervention, the most highly recommended, comprehensively researched and universally recognized treatment for autism, continues to be questioned, underfunded and ultimately threatened - but only in Quebec.

6 Apr 2011

Novartis' TOBI Podhaler receives Health Canada NOC for Pa treatment in CF patients

Novartis Canada announced today that it has received Health Canada Notice of Compliance for TOBI Podhaler, a fast and convenient inhaled therapy for cystic fibrosis patients aged six and over.

6 Apr 2011

Increased risk of virologic failure associated with NNRTI-based regimens in HIV-1 drug resistance mutations

An analysis of data from 10 studies indicates that the presence of low frequency (also called "minority") human immunodeficiency virus type 1 (HIV-1) drug resistance mutations, particularly those involving nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance, are significantly associated with an increased risk of first-line antiretroviral treatment failure, according to an article in the April 6 issue of JAMA.

6 Apr 2011

Therapy News and Research

Empire implements AGA, ACG guidelines for evaluation and management of dyspepsia and PUD

Mandometer method to treat eating disorders receives FDA clearance

Fish oil can serve as beneficial booster for tamoxifen breast cancer therapy

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Roundup: Minn. insurers to return profits above 1% from state plans; Fla. Medicaid managed care costs questioned

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

New Pipeline Embolization Device receives FDA approval for treatment of brain aneurysms

USPTO issues notice of allowance to Mirna's mir34a patent application

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

Progesterone gel can reduce preterm birth in women with short cervix

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Estrogen therapy for menopause, study looks at risks-benefits

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

ICD therapy can improve ischemic cardiomyopathy survival rates

Early Intensive Behavioural Intervention in autism continues to be questioned in Quebec

Novartis' TOBI Podhaler receives Health Canada NOC for Pa treatment in CF patients

Increased risk of virologic failure associated with NNRTI-based regimens in HIV-1 drug resistance mutations

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News